KR880701716A - 벤조[5,6]사이클로 헵타피리딘, 조성물 및 사용방법 - Google Patents

벤조[5,6]사이클로 헵타피리딘, 조성물 및 사용방법

Info

Publication number
KR880701716A
KR880701716A KR1019880700738A KR880700738A KR880701716A KR 880701716 A KR880701716 A KR 880701716A KR 1019880700738 A KR1019880700738 A KR 1019880700738A KR 880700738 A KR880700738 A KR 880700738A KR 880701716 A KR880701716 A KR 880701716A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
benzo
pyridine
formula
Prior art date
Application number
KR1019880700738A
Other languages
English (en)
Other versions
KR930002489B1 (ko
Inventor
피빈스키 죤 제이
강굴리 아쉬트 케이
그린 마이클 제이
빌라니 프랑크 제이
웡 제이
Original Assignee
스테이너 브이, 캔스타드
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테이너 브이, 캔스타드, 쉐링 코포레이션 filed Critical 스테이너 브이, 캔스타드
Publication of KR880701716A publication Critical patent/KR880701716A/ko
Application granted granted Critical
Publication of KR930002489B1 publication Critical patent/KR930002489B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)

Abstract

내용 없음

Description

벤조[5,6]사이클로 헵타피리딘, 조성물 및 사용방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 이의 염 또는 이의 용매화물.
    상기식에서, a, b, c 및 d중의 하나는 N또는 Ni9[여기서, R9는 C-, -CH3또는 -(CH2)nCO2H(여기서, n은 1 내지 3이다)이다]이고, 나머지 a, b, c 및 d그룹은 CH이며, 나머지 그룹 a, b, c 및 d는 R1또는 R2에 의해 임의로 치환될 수 있으며 ; R1및 R2는 동일하거나 상이하며, 각각 독립적으로 할로, -CF3, -OR10, -COR10, -SR10, -N(R10)2, -NC2, -OC(O)R10, -COCR10, -CCO2R11알키닐, 알케닐 또는 알킬이며, 알킬 또는 알케닐 그룹은 할로, -OR10또는 -CO2R10에 의해 치환될 수 있고 ; R3및 R4는 동일하거나 상이하며, 각각 독립적으로 H, 치환제 R1및 R2중의 하나이거나 또는 R3및 R4는 함께 포화 또는 불포화 C5-C7융합 환을 나타낼 수 있으며 ; R5, R6, R7및 R8은 각각 독립적으로 H, -CF3, 알킬 또는 아릴이며, 여기서 알킬 또는 아릴은-OR10, -SR10, N(R10)2, -NO2, COR10,OCOR10,OCO2R11,CO2R10또는 OPC3R10에 의해 치환될 수 있거나, R5,R6,R7및 R8중의 하나는 하기에서 정의하는 R과 결합하여 저급알킬, 저급알콕시, -CF3또는 아릴에 의해 치환될수 있는-(CH2)r-[여기서, r은 1 내지 4이다]을 나타내고 ; R10은 H, 알킬 또는 아릴이며 ; R11은 알킬 또는 아릴이고 ; X는 N또는 C 이며, C는 탄소원자 11에 대하여 임의의 이중결합을 함유할 수 있으며 ; 탄소원자 5 및 6사이의 점선은 임의의 이중결합이고, 이중결합이 존재하는 경우, A 및 B는 독립적으로 H,-R10, -OR10또는-OC(O)R10이며, 탄소원자 5 및 6사이에 이중결합이 존재하지 않는 경우, A 및 B는 독립적으로 H2,-(OR10, 알킬리 및 H, (알킬)2,-H 및 -OC(O)R10,H 및 OR10,=O,아릴 및 H,=NOR10또는-O-(CH2)P-O[여기서, P는2,3 또는 4이며, R10은 상기에서 정의한 바와 같다]이고 ; Z는O,S 또는 H2이며, 단(a)Z가 O인경우, R은 상기에서 정의한 바와 같이 R5,R6,R7, 또는 R8과 결합하거나 H, 아릴, 알킬, -SR11, -N(R)10)2, 사이클로알킬, 알케닐, 알키닐 또는-D를 나타내며, 여기서-D는 헤테로사이클로알킬
    또는[여기서,
    R3및 R4는 상기에서 정의한 바와같고, W는 O,S 또는 NR10이다(여기서, R10은 상기에서 정의한 바와 같다)]이고, 상기한 사이클로알킬, 알킬, 알케닐 및 알키닐은 할로, CCN(R10)2,아릴, -CO2R10, -OR12, -SR12, -N(R10)2, -N(R10)CO2R10, -CCR12, -NO2또는 D[여기서, -D 및 R10은 상기에서 정의한 바와 같고, n은 1 내지 4이며g는 0 내지 4이다)] 로부터 선택된 1 내지 3개의 그룹에 의해 임의로 치환되며, 상기한 일케닐 및 알키닐 R 그룹은 각각 이중결합 또는 삼중결합을 갖는 탄소상에-CH,-SH 또는 -N(R10)2을 함유하지 않으며 ; (b)Z가 S인 경우, R은 상기한 R그룹이외에 아릴옥시 또는 알콕시이고 ; (c)Z가 H2인 경우, R은-COOR10-E-COOR10또는 -E-OR12이다[여기서, E는-OR10, -SR10-SR-10, -N(R10)2또는-D (여기서, D, 및 R10는 상기에서 정의한 바와 같다)에 의해 치환될 수 있는 알칸디일이다]
  2. 제1항에 있어서, Z가 O또는 S인 화합물.
  3. 제1항 또는 제2항에 있어서, R이 알킬, 사이클로알킬, 알케닐, 아릴, 또는OR12, SR12, N(R10)2또는 COR12에 의해 치환된 알킬을 나타내는 화합물.
  4. 제1항에 내지 제3항중의 어느 한 항에 있어서, Z가 O인 화합물
  5. 제1항 내지 제4항중의 어느 한 항에 있어서, a가 N인 화합물
  6. 제1항 내지 제5항중 어느 한 항에 있어서, R3가 할로이고 R4가 수소인 화합물.
  7. 제1항 내지 제6항중의 어느 한 항에 있어서, R3가 할로이고 R4가 수소인 화합물.
  8. 제1항 내지 제7항중의 어느 한 항에 있어서, R5, R6, R7, 및 R8이 H인 화합물.
  9. 제1항 내지 제8항중의 어느 한 항에 있어서, A 및 B가 H인 화합물.
  10. 제1항에 있어서, 8-클로로-11-(1-아세틸-4-피페리딜리덴)-6,11-디하이드로-5-벤조[5,6]사이클로헵타[1,2-b]피리딘 8-클로로-11-(1-메록시아세틸-4-피레리딜리덴)-6,11디하이드로 1-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 ; 8-클로로-11-(1-프로피오닐-4-피페리딜리덴)6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 ; 8-플루오로-11-(1-아세틸-4-피페리딜리덴)6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 ; 9-플루오로-11-(1-아세틸-4-피페리딜리덴)-6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 ; 8-브로모-11-[1-아세틸-4-피페리딜리덴]-6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 ; 8,9-디플루오로-11-(1-아세틸-4-피레리딜리덴)-6,11디하이드로-5H-벤조[5,6]사이클로헙타[1,2-b]피리딘 ; 8-클로로-11-(1-아세틸-4-피페리디닐)-6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 ; 11-(-아세틸-4-피페리딜)-6,11-디하이드로-5H-벤조[5,6]사이클로헙타[1,2-b]피리딘 ; 11(1-아세틸-4-피페리딜)-6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 또는 8-클로로-11-(1-아세틸-4-피페라지닐)-6,11-디하이드로-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘인 화합물.
  11. 제1항 내지 제10항중의 어느 한 항에서 정의한 화합물을 약제학적으로 허용되는 담체와 혼합한 약제학적 조성물.
  12. 일반식(Ⅰ)의 화합물을 약제학적으로 허용되는 담체와 혼합시킴을 특징으로하여 약제학적 조성물을 제조하는 방법.
  13. a)일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물과 반응시키거나, b)일반식(Ⅲ)의 화합물을 사용하여 일반식(Ⅴ)의 N-알킬화합물을 직접 전화시키거나, C)일반식(XII)의 화합물을 폐환시킴을 특징으로하여 제1항에서 정의한 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기에서, L은 이탈그룹이다.
  14. 일반식(XII)의 화합물.
    상기식에서, 치환제들은 제1항의 일반식(Ⅰ)에서 정의한 바와 같다.
  15. 염증 및/또는 알러지 치료용 약제학적 조성물을 제조하기 위한, 제1항에서 청구한 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880700738A 1986-10-31 1987-10-29 벤조[5, 6]사이클로헵타피리딘 및 이의 제조방법 KR930002489B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/925,342 US4826853A (en) 1986-10-31 1986-10-31 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US925342 1986-10-31
PCT/US1987/002777 WO1988003138A1 (en) 1986-10-31 1987-10-29 Benzo[5,6]cycloheptapyridines, compositions and methods of use

Publications (2)

Publication Number Publication Date
KR880701716A true KR880701716A (ko) 1988-11-04
KR930002489B1 KR930002489B1 (ko) 1993-04-02

Family

ID=25451584

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880700738A KR930002489B1 (ko) 1986-10-31 1987-10-29 벤조[5, 6]사이클로헵타피리딘 및 이의 제조방법

Country Status (22)

Country Link
US (1) US4826853A (ko)
EP (3) EP0685476A1 (ko)
JP (1) JPH0678316B2 (ko)
KR (1) KR930002489B1 (ko)
AT (1) ATE116310T1 (ko)
AU (1) AU604285B2 (ko)
CA (2) CA1305147C (ko)
CS (1) CS414391A3 (ko)
DE (1) DE3750929T2 (ko)
DK (1) DK73193A (ko)
ES (1) ES2068179T3 (ko)
FI (1) FI96768C (ko)
HK (1) HK186396A (ko)
IE (1) IE65174B1 (ko)
IL (1) IL84310A0 (ko)
MY (1) MY102986A (ko)
NZ (1) NZ222347A (ko)
OA (1) OA09546A (ko)
PH (1) PH26184A (ko)
SG (1) SG44597A1 (ko)
WO (1) WO1988003138A1 (ko)
ZA (1) ZA878128B (ko)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007193A (en) * 1959-01-12 1961-11-07 Nat Glass Company Inc Adjustable hinge
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5665726A (en) * 1986-10-31 1997-09-09 Schering Corporation Benzo[5,6]cycloheptapyridines, compositions and methods of use
US5438062A (en) * 1986-10-31 1995-08-01 Schering Corporation Benzo(5,6)cycloheptapyridines, compositions and methods of use
CA1341044C (en) * 1988-04-28 2000-07-04 Frank J. Villani Benzopyrido piperidine, piperidylidene and peperazine compounds, compositions, methods of manufacture and methods of use
DE68926976T2 (de) * 1988-04-28 1997-02-27 Schering Corp Kondensierte polyzyklische Verbindungen, Zusammenstellungen, Verfahren zur Herstellung und deren Anwendung als PAF-antagonistische, antihistaminische und/oder anti-inflammatorische Agenzien
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
ES2012297A6 (es) * 1989-04-10 1990-03-01 Espnola De Especialidades Farm Procedimiento para la obtencion de nuevos derivados imidazolicos diclorados con actividad antifungica.
AU620996B2 (en) * 1989-07-04 1992-02-27 Hokuriku Pharmaceutical Co. Ltd. 4-{(dibenzocycloheptene) or (dibenzoxepin)}-1-substituted piperidines
IL98572A (en) * 1990-06-22 1995-07-31 Schering Corp Bite-benzo or benzopyrido compounds Cyclohepta piperidine, piperidylidene and piperazine, preparations and methods of use.
EP0552292B1 (en) * 1990-10-10 1995-06-21 Schering Corporation Substituted imidazobenzazepines and imidazopyridoazepines
AU646519B2 (en) * 1990-10-10 1994-02-24 Schering Corporation Pyridine and pyridine N-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and methods of use thereof
CA2093646A1 (en) * 1990-10-10 1992-04-11 Jesse K. Wong Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
JPH06508129A (ja) * 1991-05-23 1994-09-14 シェリング・コーポレーション 新規のベンゾピリドピペリジリデン化合物、組成物、製造法および使用法
AU2392392A (en) * 1991-07-23 1993-02-23 Schering Corporation Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
JP2974529B2 (ja) * 1992-02-20 1999-11-10 北陸製薬株式会社 両性型三環系化合物
ES2089815T3 (es) * 1992-03-27 1996-10-01 Schering Corp Derivados de bis-aril-carbinol sin enlaces de puente, composiciones y metodos de uso.
DE69310904T2 (de) * 1992-03-27 1997-08-28 Schering Corp Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
WO1993023400A1 (en) * 1992-05-19 1993-11-25 Schering Corporation Pentacyclic antihistamines
ES2042421B1 (es) * 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
CN1042228C (zh) * 1993-07-13 1999-02-24 詹森药业有限公司 抗过敏咪唑并吖庚因
TW308594B (ko) * 1993-10-15 1997-06-21 Schering Corp
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6075025A (en) 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ES2087818B1 (es) * 1993-11-24 1997-03-16 Uriach & Cia Sa J 8-cloro-11-(1-((5-metil-3-piridil)metil)-4-piperidiliden)-6,11-dihidro-5h-benzo-(5,6)cicloheptal(1,2-b)piridina, fumarato.
US5574173A (en) * 1993-12-06 1996-11-12 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5464840A (en) * 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5538986A (en) * 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
ES2080700B1 (es) * 1994-07-27 1996-10-16 Farmihispania S A Nuevo procedimiento para la obtencion de loratadina.
ES2080699B1 (es) * 1994-07-27 1996-10-16 Farmahispania S A Nuevos derivados de 2-(1-etoxicarbonil-4-piperidiliden)metil)piridina y un procedimiento para su obtencion.
ES2087026B1 (es) * 1994-07-28 1997-03-16 Uriach & Cia Sa J Nuevo derivado de la benzo(5,6)ciclohepta- (1.2-b) piridina.
US5461057A (en) * 1994-09-08 1995-10-24 Schering Corporation Hydro-ethano-indeno-pyridines
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5891872A (en) * 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
CN1047774C (zh) * 1996-09-10 1999-12-29 上海华联制药有限公司 氮杂二苯并环庚烯酮类化合物的制备方法
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
SK33899A3 (en) * 1996-09-13 2000-02-14 Schering Corp Tricyclic inhibitors of farnesyl protein transferase
ES2234036T3 (es) * 1996-09-13 2005-06-16 Schering Corporation Compuestos utiles para inhibir la farnesil-protein-transferasa.
EP0942906B1 (en) * 1996-09-13 2004-11-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
DE69731544T2 (de) * 1996-09-13 2005-10-27 Schering Corp. Trizyklische antitumor verbindungen mit farnesyl protein transferase inhibierender wirkung
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6159984A (en) * 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
WO1998057959A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
ES2174450T3 (es) * 1997-06-17 2002-11-01 Schering Corp Derivados de benzo(5,6)ciclohepta(1,2-b)piridina como inhibidores de la farnesil-protein-transferasa.
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
HUP0002186A3 (en) * 1997-06-17 2002-04-29 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
US5945430A (en) * 1997-06-17 1999-08-31 Schering Corporation Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
CA2293368C (en) * 1997-06-17 2009-01-20 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives useful for inhibition of farnesyl protein transferase
CN1134433C (zh) * 1997-06-17 2004-01-14 先灵公司 法呢基蛋白转移酶的新的氨基氧酰胺三环抑制剂
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6686502B1 (en) 1999-03-26 2004-02-03 Ucb S.A. Compounds and methods for treatment of asthma, allergy and inflammatory disorders
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ATE352549T1 (de) * 2002-09-24 2007-02-15 Morepen Lab Ltd Verfahren zur herstellung von desloratadin
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
US8207186B2 (en) 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
CA2624676A1 (en) 2005-10-21 2007-05-03 Jongwon Lim Tyrosine kinase inhibitors
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
US20080287481A1 (en) * 2006-09-08 2008-11-20 Mayur Devjibhai Khunt Process for the preparation of desloratadine polymorph mixtures
CN103113348B (zh) * 2013-02-18 2015-03-25 扬子江药业集团江苏海慈生物药业有限公司 枸地氯雷他定的假多晶型及其制备方法
CN110818684B (zh) * 2019-10-08 2023-04-07 深圳市南山区人民医院 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-SH及其用途
CN110845473B (zh) * 2019-10-08 2023-04-07 深圳市南山区人民医院 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-乙酸乙酯及其用途
CN110818685A (zh) * 2019-10-08 2020-02-21 深圳市南山区人民医院 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-异己基及其用途
MX2022005102A (es) * 2019-10-31 2022-05-30 Jd Bioscience Inc Compuesto triciclico y uso farmaceutico del mismo.
WO2023071601A1 (zh) * 2021-10-28 2023-05-04 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途
CN115141229B (zh) * 2022-07-21 2023-12-12 华创合成制药股份有限公司 抗组胺类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (ko) * 1963-04-24
US3419565A (en) * 1963-04-24 1968-12-31 Schering Corp Aza-dibenzocycloheptenes
US3409621A (en) * 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3717647A (en) * 1971-04-09 1973-02-20 Schering Corp Alpha-nicotinoyl phenylacetonitriles
DE2640022A1 (de) * 1975-09-15 1977-03-24 Sandoz Ag Neue organische verbindungen, ihre herstellung und verwendung
US4335036A (en) 1980-05-30 1982-06-15 E. I. Du Pont De Nemours And Company Plasticized polyvinyl butyral employing propylene oxide oligomers
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4355036A (en) * 1980-06-19 1982-10-19 Schering Corporation Tricyclic-substituted piperidine antihistamines
AU570306B2 (en) * 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
EP0208855B1 (en) * 1985-05-13 1991-03-06 Schering Corporation process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines

Also Published As

Publication number Publication date
JPH02500910A (ja) 1990-03-29
IE872913L (en) 1988-04-30
HK186396A (en) 1996-10-11
EP0270818A1 (en) 1988-06-15
NZ222347A (en) 1990-03-27
IE65174B1 (en) 1995-10-04
DK73193D0 (da) 1993-06-21
EP0685476A1 (en) 1995-12-06
CA1305147C (en) 1992-07-14
IL84310A0 (en) 1988-03-31
WO1988003138A1 (en) 1988-05-05
DE3750929D1 (de) 1995-02-09
ATE116310T1 (de) 1995-01-15
CA1321589C (en) 1993-08-24
JPH0678316B2 (ja) 1994-10-05
FI96768B (fi) 1996-05-15
PH26184A (en) 1992-03-18
AU8336287A (en) 1988-05-25
CS414391A3 (en) 1992-09-16
AU604285B2 (en) 1990-12-13
FI96768C (fi) 1996-08-26
FI891806A (fi) 1989-04-17
DE3750929T2 (de) 1995-06-01
EP0330673A1 (en) 1989-09-06
SG44597A1 (en) 1997-12-19
FI891806A0 (fi) 1989-04-17
DK73193A (da) 1993-06-21
US4826853A (en) 1989-05-02
ES2068179T3 (es) 1995-04-16
KR930002489B1 (ko) 1993-04-02
EP0270818B1 (en) 1994-12-28
OA09546A (en) 1993-01-31
MY102986A (en) 1993-03-31
ZA878128B (en) 1988-04-29

Similar Documents

Publication Publication Date Title
KR880701716A (ko) 벤조[5,6]사이클로 헵타피리딘, 조성물 및 사용방법
KR920700209A (ko) 치환된 벤조[5,6]사이클로헵타피리딘의 헤테로사이클릭 n-옥사이드 유도체, 조성물 및 용도
AU554358B2 (en) Thieno(3,2-c)pyridine derivatives
HUT54981A (en) Process for producing acryloyl-substituted pyrrole derivatives and pharmaceutical compositions comprising same
IL91167A (en) Substituted 2-(imidazolymethyl)-pyrido- (and azepino-) indol-1-one derivatives, their preparation and pharmaceutical compositions containing them
LTIP603A (en) Novel esters, method for the preparation thereof and pharmaceutical composition
GB1125112A (en) New derivatives of diazabicyclo-decane and process for preparing them
GB8330097D0 (en) Cyclic ethers
EP0276163A3 (en) Indole derivatives
HUT45059A (en) Process for producing abeoergoline derivatives
IL87107A0 (en) Naphthothiazepine derivatives,their preparation and pharmaceutical compositions containing them
ZA81348B (en) Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof,processes for their preparation and pharmaceutical compositions
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure
IE44349L (en) DERIVATIVES OF 4H-THIENO [3,2-b] [1] BENZAZEPINES
GB1066266A (en) Diazepine derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990402

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee